Krsnaa Diagnostics Board Approves Q1 FY27 Results, Recommends Dividend, Plans Warrants
Krsnaa Diagnostics reported Q1 FY27 results with consolidated revenue of ₹235.53 crore and standalone profit before tax of ₹540.32 million. The Board approved the Q1 FY27 results and recommended a final dividend of ₹2.00 per share. The 16th AGM is on September 28, 2026. The company will issue 16.21 lakh warrants to promoters at a price higher of ₹565 or floor price.
The issuance of warrants to promoters, the dividend declaration, and the approval of financial results are material events for the company. While the tax assessment is noted, the management's view of no material impact lessens its immediate impact.
The announcement includes both positive aspects like dividend declaration and warrant issuance, and routine financial results. The tax assessment note introduces a neutral to slightly negative undertone, but management's confidence in no material impact balances it out.
Krsnaa Diagnostics Limited announced the outcome of its Board Meeting held on August 13, 2026. The Board approved the Unaudited (Standalone and Consolidated) Financial Results for the quarter ended June 30, 2026, along with the Limited Review Reports.
The Board also approved the Director's Report and Annexures forming part of the Annual Report for the financial year 2025-26. The 16th Annual General Meeting (AGM) is scheduled to be held on Monday, September 28, 2026, at 11:00 Hrs. (IST) through physical mode. The record date for the payment of the final dividend is Friday, September 18, 2026, with book closure from Saturday, September 19, 2026, to Monday, September 28, 2026. The dividend declared by the Board on May 25, 2026, was ₹2.00 per share for FY 2024-25.
Additionally, the Board approved the issuance of 16,21,000 share warrants to Mr. Rajendra Mutha and Krsna Diagnostics (Mumbai) Private Limited (Promoter and Promoter Group) at an issue price to be determined in the future, which will be the higher of the floor price or ₹565/-
The financial results for the quarter ended June 30, 2026, showed consolidated revenue from operations of ₹235.53 crore (INR 2,355.32 million) and a profit before tax of ₹224.36 million. Standalone revenue from operations was ₹210.66 crore (INR 2,106.61 million) with a profit before tax of ₹540.32 million.
The company also addressed tax assessments for various Assessment Years, stating that based on expert opinions, the demand orders are not tenable and are not expected to have a material impact on the Group's financial position.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.